Voyager Therapeutics is a biotechnology company focused on developing innovative gene therapies for neurological diseases
The company utilizes its proprietary adeno-associated viral (AAV) platform to create targeted treatments aimed at addressing disorders such as Parkinson's disease, Huntington's disease, and other neurodegenerative conditions. By leveraging advancements in gene delivery techniques, Voyager Therapeutics aims to provide long-lasting solutions that potentially improve the quality of life for patients suffering from these debilitating illnesses. Their commitment to scientific research and clinical development centers around delivering transformative therapies to address significant unmet medical needs in neurology.
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Dave, Inc. (NASDAQ: DAVE), Red Cat Holdings, Inc. (NASDAQ: RCAT), Perpetua Resources Corp. (NASDAQ:PPTA), and Voyager Therapeutics, Inc. (NASDAQ:VYGR). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR) on behalf of Voyager stockholders. Our investigation concerns whether Voyager has violated the federal securities laws and/or engaged in other unlawful business practices.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. (“Voyager” or “the Company”) (NASDAQ: VYGR) for violations of the securities laws.
The article outlines three high-growth stocks that could double by 2025, using specific screening criteria: strong buy ratings from multiple analysts, significant revenue and earnings growth, and substantial recent earnings surprises.
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term value.
